TY - T1的哮喘治疗调节priming-associated血液嗜酸性粒细胞反应过敏性哮喘患者JF -欧洲呼吸杂志》乔欧元和J SP - 915 LP - 922 - 10.1034 / j.1399-3003.1999.14d31。x六世- 14 - 4盟JC grutter AU - L Brinkman AU - MM Aslander AU - JM van den博世AU - L Koenderman AU JW拉默斯Y1 - 1999/10/01 UR - //www.qdcxjkg.com/content/14/4/915.abstract N2 -嗜酸性粒细胞哮喘的发病机制中发挥重要作用。体内一些嗜酸性粒细胞炎性反应还是会在这个疾病。本研究的目的是调查是否定期antiasthma治疗可以调节priming-sensitive人类嗜酸性粒细胞的细胞毒性机制。two-centre在一项随机,双盲平行小组研究,8周治疗的效果与氟替卡松加沙美特罗xinafoate 50 microg b.i.d。二丙酸倍氯米松400 microg b.i.d.或肺功能和嗜酸性粒细胞激活priming-sensitive细胞毒性机制,即脱粒的嗜酸性粒细胞阳离子蛋白(ECP)血清中,孤立的上下文中的嗜酸性粒细胞诱导和激活的呼吸爆发和释放platelet-activating因子(PAF)参谋长进行了测试。这些影响在40过敏性哮喘患者进行评估之前和过敏原吸入后24 h的挑战。而基线在一秒用力呼气量(FEV1)在所有治疗组改善,只有治疗氟替卡松加沙美特罗和倍氯米松显著地抑制allergen-induced增加血清ECP,和(启动/未灌注的)PAF-release,表明抑制嗜酸性粒细胞过敏原后启动的挑战。在联合治疗相比,单倍氯米松没有影响allergen-induced PAF-release,建议额外氟替卡松加沙美特罗联合治疗期间的抗炎作用。单倍氯米松抑制了prechallenge serum-treated酵母聚糖(STZ)(0.1毫克毫升(1)全身的呼吸爆发和allergen-induced增加血清ECP水平,反映了预处理和postchallenge抗炎作用。 During monotherapy with salmeterol, an allergen-induced increase in serum ECP concentration and STZ (0.1 mg x mL(-1))-induced respiratory burst was observed, suggesting that treatment with salmeterol alone had no effect on priming-sensitive eosinophil cytotoxic mechanisms. In conclusion, this study shows that standard asthma therapy leads to inhibition of eosinophil priming of cytotoxic mechanisms in vivo. ER -